Granisetron Hydrochloride Tablet
NDC Package 51991-735-32
Package Information
Granisetron Hydrochloride tablets is uSP are indicated for the prevention of:Nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin.Nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation. This formulation utilizes a tablet delivery system. Marketed by Breckenridge Pharmaceutical, Inc., this product is identified by NDC 51991-735 and is authorized under FDA application ANDA078969.
Identification & Billing
- RxCUI: 310599 - granisetron HCl 1 MG Oral Tablet
- RxCUI: 310599 - granisetron 1 MG Oral Tablet
- RxCUI: 310599 - granisetron 1 MG (granisetron hydrochloride 1.12 MG) Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 51991 - Breckenridge Pharmaceutical, Inc.
- 51991-735 - Granisetron Hydrochloride
- 51991-735-32 - 1 BLISTER PACK in 1 CARTON / 2 TABLET in 1 BLISTER PACK
- 51991-735 - Granisetron Hydrochloride
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (51991-735). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 51991-735-32 identifies a specific commercial package of 1 blister pack in 1 carton / 2 tablet in 1 blister pack of Granisetron Hydrochloride, a human prescription drug labeled by Breckenridge Pharmaceutical, Inc.. This tablet is formulated for oral use and contains granisetron hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Breckenridge Pharmaceutical, Inc. on June 22, 2009. The current certification is valid through December 31, 2026.
How is this Breckenridge Pharmaceutical, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 51991073532. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.